IP Library Granted Patent US 8,178,564
Granted Patent B2
US 8,178,564 · App. 12/367,394 · Granted May 15, 2012

Use of picoplatin to treat colorectal cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,564
App. No.
12/367,394
Granted
May 15, 2012
Kind
B2
Abstract

The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.

Claims (6)

1. A method of treatment of metastatic colorectal cancer comprising administering to a patient afflicted with metastatic colorectal cancer and not previously treated systemically for said cancer, leucovorin, at a dosage of about 400 mg/m 2 , as a 2 hour infusion, the administration of the leucovorin being followed by a 5-fluorouracil (5-FU) bolus at a dosage of about 400 mg/m 2 ; the 5-FU bolus being followed by 5-FU at a dosage of about 2,400 mg/m 2 administered as a 46 hour continuous infusion; wherein the leucovorin and the 5-FU are administered to the patient every 2 weeks and administering about 60-150 mg/m 2 of picoplatin to the patient simultaneously with the leucovorin every 4 weeks, wherein at least the initial dose of picoplatin is about 150 mg/m 2 wherein a cumulative dose of picoplatin of greater than about 900 mg/m 2 is delivered to the patient.

2. The method of claim 1 wherein the patient has previously had surgery to remove or de-bulk a colorectal tumor.

3. The method of claim 1 wherein the administration is effective to prevent or delay development or metastasis of the colorectal cancer.

4. The method of claim 1 wherein a subsequent dose of picoplatin is administered at about a 15-30 mg/m 2 lower dose than a previous dose.

5. The method of claim 1 wherein the picoplatin is administered at least once at a dosage of about 60-75 mg/m 2 .

6. The method of claim 1 further comprising administration of a 5-HT 3 receptor antagonist.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2016
From: TALLIKUT PHARMACEUTICALS, INC.
To: ACCELERATED PHARMA, INC.
Reel/Frame 038528/0599 →
MERGER Recorded Dec 9, 2014
From: ENCARTA, INC.
To: TALLIKUT PHARMACEUTICALS, INC.
Reel/Frame 034436/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: PONIARD PHARMACEUTICALS, INC.
To: PONIARD (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 034437/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2014
From: PONIARD (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: ENCARTA, INC.
Reel/Frame 034439/0001 →
RELEASE OF SECURITY INTEREST Recorded May 21, 2014
From: SCHWEGMAN, LUNDBERG& WOESSNER, P.A.
To: POINARD PHARMACEUTICALS, INC.
Reel/Frame 032981/0663 →
LIEN Recorded Apr 16, 2012
From: PONAIRD PHARMACEUTICALS, INC.
To: SCHWEGMAN, LUNDBERG& WOESSNER, P.A.
Reel/Frame 028052/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2009
From: KARLIN, DAVID A.; BREITZ, HAZEL B.; WEIDEN, PAUL L.
To: PONIARD PHARMACEUTICALS, INC.
Reel/Frame 022376/0357 →